Smart Nanoparticles Show Promise Against Deadliest Brain Cancer
Researchers developed innovative nanoparticles that act like a surgeon's flashlight during glioblastoma operations to locate tiny cancer clusters, then destroy remaining cancer cells with light activation. In mouse studies, treated animals survived 60 days compared to 42 days with surgery alone.
The Problem with Glioblastoma
Glioblastoma is the most aggressive form of brain cancer. It's difficult to treat because tumor cells infiltrate the surrounding brain tissue, making it hard for surgeons to remove the cancer completely without damaging healthy tissue. All these factors contribute to a five-year survival rate of only around 7%.
The Dual-Function Solution
Scientists have developed an innovative nanoparticle platform that could help surgeons remove glioblastoma, the deadliest form of brain cancer, while also destroying microscopic cancer cells left behind after surgery. Researchers from the University of Technology Sydney (UTS), Harvard and Henan universities have discovered a "double-punch" nanozyme platform designed to address both problems with a single tool: smart nanoparticles.
How the Nanoparticles Work
The two-phase approach leverages the same material for different purposes. During surgery, the nanoparticles act as an imaging guide. A specially designed fluorescent dye glows under near-infrared light, allowing surgeons to identify tumour cell clusters as small as 44 micrometres—far beyond the resolution of current clinical imaging. A targeting molecule also helps the material cross the blood-brain barrier and selectively accumulate inside glioblastoma cells.
After tumor removal, the treatment continues. After surgeons remove the visible tumour, the same material is applied to the surgical cavity and reactivated with near-infrared light. The platinum atoms convert the tumour's hydrogen peroxide into oxygen, helping overcome the low-oxygen environment that protects cancer cells. At the same time, the light generates heat and reactive molecules that destroy remaining microscopic cancer cells.
Preclinical Results
In mouse models, the approach completely prevented tumour recurrence during the study period, with 100% of treated mice surviving for 60 days, compared with 42 days for animals treated with surgery alone. The findings are published in Science Translational Medicine.